Spotlight on Fulvestrant in Hormone Receptor-Positive Metastatic Breast Cancer in Postmenopausal Women with Disease Progression Following Antiestrogen Therapy

By Kate McKeage   Monique P. Curran   Greg L. Plosker  

American Journal of Cancer, Vol. 3, Iss. 4, 2004-01 ,pp. : 267-270

Adis International

Access to resources Recommend Favorite

Investigating the discernible and distinct effects of platinumbased chemotherapy regimens for metastatic triplenegative breast cancer on time to progression

By                  

Oncology Letters, Vol. 7, Iss. 3, 2014-01 ,pp. : 866-870

Spandidos Publications

Access to resources Recommend Favorite

Fulvestrant in Advanced Male Breast Cancer

By Agrawal Amit   Cheung Kwok-Leung   Robertson John FR  

Breast Cancer Research and Treatment, Vol. 101, Iss. 1, 2007-01 ,pp. : 123-123

Springer Publishing Company

Access to resources Recommend Favorite

Ki67 expression in the primary tumor predicts for clinical benefit and time to progression on first-line endocrine therapy in estrogen receptor-positive metastatic breast cancer

By Delpech Y.  

Breast Cancer Research and Treatment, Vol. 135, Iss. 2, 2012-09 ,pp. : 619-627

Springer Publishing Company

Access to resources Recommend Favorite

Use of the metastatic breast cancer progression (MBC-P) questionnaire to assess the value of progression-free survival for women with metastatic breast cancer

By Hurvitz Sara   Lalla Deepa   Crosby Ross   Mathias Susan  

Breast Cancer Research and Treatment, Vol. 142, Iss. 3, 2013-12 ,pp. : 603-609

Springer Publishing Company

Access to resources Recommend Favorite